MedTrace Logo

Central Hemodynamic and Sodium Urinary

NCT03932422 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-02-09

No results posted yet for this study

Summary

Systemic arterial hypertension is one of major risk factors to development of target organ damage that culminate in cardiovascular diseases such as acute myocardial infarction and stroke. Sodium intake is related with elevation of arterial blood pressure due to rise of cardiac output and of arterial stiffness and it can be estimated by daily sodium excreted in urine 24h. Ambulatory Blood Pressure Monitoring can be used to obtain peripheral and central hemodynamic parameters \[arterial stiffness parameters - central blood pressure, pulse wave velocity and augmentation index\]. Applanation tonometry also can be used to check same central hemodynamic parameters. Both methods provide us important informations about the patients clinical conditions and help us to infer their prognosis. Therefore, this protocol aims measure the central hemodynamic parameters in hypertensive patients, controlled or resistant, and evaluate their sodium urinary excretion. The hypothesis is the resistant hypertensive patients have parameters higher than controlled hypertensive patients.

Conditions

Interventions

DIAGNOSTIC_TEST

Evaluate if the individuals are resistant hypertensive patients

Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.

Sponsors & Collaborators

  • Sao Jose do Rio Preto Medical School

    collaborator OTHER

  • Hospital de Base

    lead OTHER

Principal Investigators

  • José F Vilela-Martin, MD PhD FAHA · State Medical School at São José do Rio Preto (FAMERP), São Paulo, Brazil

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-15
Primary Completion
2021-02-15
Completion
2021-03-15

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03932422 on ClinicalTrials.gov